Drug Profile
Bevacizumab biosimilar - TOT Biopharm
Alternative Names: Pusintin; TAB008; TOT102Latest Information Update: 25 Apr 2022
Price :
$50
*
At a glance
- Originator TOT Biopharm
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cervical cancer; Colorectal cancer; Glioblastoma; Non-small cell lung cancer; Ovarian cancer
Most Recent Events
- 25 Apr 2022 Launched for Cervical cancer in China (IV) before April 2022 (TOT Biopharm pipeline, April 2022)
- 25 Apr 2022 Launched for Colorectal cancer (Metastatic disease) in China (IV) before April 2022 (TOT Biopharm pipeline, April 2022)
- 25 Apr 2022 Launched for Glioblastoma in China (IV) before April 2022 (TOT Biopharm pipeline, April 2022)